We have identified a list of several trending healthtech stocks that appear have recently received buy ratings from top Wall Street analysts and are showing positive investor sentiment, as well as news headlines. With that said, our editors here at healthtechmovers.com, are adding these healthtech companies to our watchlist to see if this momentum continues. Our watchlist includes trending
Summary: Eli Lilly and Company, one of the world's largest pharmaceutical companies, boasts a diversified product profile including a solid lineup of new successful drugs. It also has a dependable pipeline as it navigates through challenges like patent expirations of several drugs and rising pricing pressure on its U.S. diabetes franchise. Its pharmaceutical product categories are neuroscience, diabetes, oncology, immunology and others. Over the past few years, Lilly has been actively seeking acquisitions and in-licensing deals to boost its product portfolio and pipeline. The purchase of ImClone Systems brought with it cancer compound, Erbitux. The acquisition of ICOS Corporation gave Lilly full control over erectile dysfunction drug, Cialis. Its other acquisitions include Hypnion, Inc., CoLucid Pharmaceuticals added Reyvow for acute migraine, Loxo Oncology and Dermira. Lilly has collaboration agreements with several companies including Incyte, Boehringer Ingelheim and Innovent Biologics among others.
- Recent LLY Stock Price: $757.64
- Yearly Gain for LLY stock: 143.44%
- Market Cap for LLY stock: $719.88B
- P/E Ratio for LLY stock: 130.4
Will LLY's stock price go up? Is there an accurate LLY stock forecast available?
TipRanks.com reports that Eli Lilly and Company currently has 5 analysts offering 12-month price targets and the consensus is a Buy rating with an average price target is $828.38. The target pricing ranges from a high LLY forecast of $885 down to a low forecast of $771.92. Eli Lilly and Company (LLY)’s last closing stock price was $757.64 which would put the average price target at 9.34% upside.
In addition, TradingView issued a buy rating for LLY stock over the next month, Barchart.com has a Strong buy rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on LLY stock.
Other analysts covering LLY include:
- Akash Tewari of Jefferies issued a Buy rating with the price target of $885 on 1 day ago
- Carter Gould of Barclays issued a Buy rating with the price target of $810 on 1 day ago
- Mohit Bansal of Wells Fargo issued a Buy rating with the price target of $825 on 1 day ago
- Kerry Holford of Berenberg Bank issued a Buy rating with the price target of $850 on 1 day ago
If you are wondering if LLY is a good stock to buy, here are 3rd party ratings for LLY stock:
- TipRanks.com: Buy
- TradingView.com: buy
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: Strong buy
- Zacks.com: Hold, Bottom 30% (174 out of 250)
What is the sentiment on the street regarding Eli Lilly and Company? (Current ratings compiled by TipRanks.com)
- News Sentiment for LLY stock: Bearish
- Blogger Consensus for LLY stock:
- Media Buzz for LLY stock: Strong Buy
- Insider Signal for LLY stock: Selling
- Investor Sentiment for LLY stock: Positive
- Hedge Fund signal for LLY stock: Medium Risk
The stock market is extremely volatile, and you need to do your own research on LLY stock including scouring the social networks like LLY StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for LLY stock chart >>
Summary: Regeneron is a biotechnology company focused on the discovery, development and commercialization of treatments targeting serious medical conditions. The company's portfolio boasts nine marketed drugs - Eylea, Dupixent, Praluent, Kevzara, Libtayo, Evkeeza, Inmazeb Arcalyst and Zaltrap. The company also developed an antibody cocktail for COVID-19, REGEN-COV. REGEN-COV is a cocktail of two monoclonal antibodies and was designed specifically to block the infectivity of SARS-CoV-2, the virus that causes COVID-19. Regeneron has a collaboration agreement with Roche for the same. While Regeneron has co-developed Eylea with Bayer's HealthCare unit, Praluent was co-developed with Sanofi. Regeneron collaborated with Bayer for the joint development and commercialization of co-formulated combinations of Eylea, rinucumab and nesvacumab for the treatment of ocular diseases or disorders outside the United States.
- Recent REGN Stock Price: $987.61
- Yearly Gain for REGN stock: 29.88%
- Market Cap for REGN stock: $106.61B
- P/E Ratio for REGN stock: 28.38
Will REGN's stock price go up? Is there an accurate REGN stock forecast available?
TipRanks.com reports that Regeneron Pharmaceuticals, Inc. currently has 5 analysts offering 12-month price targets and the consensus is a Buy rating with an average price target is $1,071.44. The target pricing ranges from a high REGN forecast of $981.2 down to a low forecast of $1050. Regeneron Pharmaceuticals, Inc. (REGN)’s last closing stock price was $987.61 which would put the average price target at 8.49% upside.
In addition, TradingView issued a buy rating for REGN stock over the next month, Barchart.com has a Strong buy rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on REGN stock.
Other analysts covering REGN include:
- Robyn Karnauskas of Truist Financial issued a Buy rating with the price target of $981.2 on 1 day ago
- Evan Seigerman of BMO Capital issued a Buy rating with the price target of $1082 on 5 days ago
- Jasper Hellweg of Argus Research issued a Buy rating with the price target of $1060 on 1 week ago
- Carter Gould of Barclays issued a Buy rating with the price target of $1050 on 2 weeks ago
If you are wondering if REGN is a good stock to buy, here are 3rd party ratings for REGN stock:
- TipRanks.com: Buy
- TradingView.com: buy
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: Strong buy
- Zacks.com: Hold, Top 34% (85 out of 250)
What is the sentiment on the street regarding Regeneron Pharmaceuticals, Inc.? (Current ratings compiled by TipRanks.com)
- News Sentiment for REGN stock: Bearish
- Blogger Consensus for REGN stock:
- Media Buzz for REGN stock: Strong Buy
- Insider Signal for REGN stock: Selling
- Investor Sentiment for REGN stock: Positive
- Hedge Fund signal for REGN stock: Medium Risk
The stock market is extremely volatile, and you need to do your own research on REGN stock including scouring the social networks like REGN StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for REGN stock chart >>
Summary: Biogen Inc. is one of the world's leading biotechnology companies which focuses on developing innovative therapies for treating serious neurological and neurodegenerative diseases, including its core growth areas of multiple sclerosis (MS) and neuroimmunology, Alzheimer's disease (AD) and dementia, movement disorders including Parkinson's disease, neuromuscular disorders, including spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS) and ophthalmology. Key multiple sclerosis/MS drugs in its portfolio are Tecfidera, Vumerity, Avonex, Plegridy, Fampyra and Tysabri. Other approved/marketed products include Fumaderm (severe psoriasis), Spinraza (spinal muscular atrophy (SMA)) and Aduhelm (Alzheimer's disease).
- Recent BIIB Stock Price: $221.74
- Yearly Gain for BIIB stock: -17.83%
- Market Cap for BIIB stock: $32.23B
- P/E Ratio for BIIB stock: 27.82
Will BIIB's stock price go up? Is there an accurate BIIB stock forecast available?
TipRanks.com reports that Biogen Inc. currently has 5 analysts offering 12-month price targets and the consensus is a Buy rating with an average price target is $301.40. The target pricing ranges from a high BIIB forecast of $364 down to a low forecast of $250. Biogen Inc. (BIIB)’s last closing stock price was $221.74 which would put the average price target at 35.92% upside.
In addition, TradingView issued a sell rating for BIIB stock over the next month, Barchart.com has a Strong sell rating and Yahoo! Finance has a Neutral short-term outlook. Remember, securities are volatile, so please do your own research on BIIB stock.
Other analysts covering BIIB include:
- Salim Syed of Mizuho Securities issued a Buy rating with the price target of $277 on 6 days ago
- Sumant Kulkarni of Canaccord Genuity issued a Buy rating with the price target of $305 on 1 week ago
- Eric Schmidt FCA of Cantor Fitzgerald issued a Buy rating with the price target of $311 on 1 week ago
- Colin Bristow of UBS issued a Hold rating with the price target of $250 on 1 week ago
If you are wondering if BIIB is a good stock to buy, here are 3rd party ratings for BIIB stock:
- TipRanks.com: Buy
- TradingView.com: sell
- Yahoo! Finance: Neutral Short-Term Outlook
- Barchart.com: Strong sell
- Zacks.com: Hold, Top 34% (85 out of 250)
What is the sentiment on the street regarding Biogen Inc.? (Current ratings compiled by TipRanks.com)
- News Sentiment for BIIB stock: Bearish
- Blogger Consensus for BIIB stock:
- Media Buzz for BIIB stock: Buy
- Insider Signal for BIIB stock: Balanced
- Investor Sentiment for BIIB stock: Negative
- Hedge Fund signal for BIIB stock: Medium Risk
The stock market is extremely volatile, and you need to do your own research on BIIB stock including scouring the social networks like BIIB StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for BIIB stock chart >>
One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals. TipRanks.com tracks and measures the performance of over 50,000 financial experts. The TipRanks Star Ranking TM is calculated based on expert success rate, average return and statistical significance. Get more from TipRanks.com here >>
The Editor, HealthTechMovers.com
HealthTechMovers.com (HTM) is built for investors who are interested in healthcare stocks, health insurance stocks, healthcare technology stocks, biotechnology stocks, pharmaceutical stocks, healthcare service provider stocks, life science stocks and more. HTM aggregates market data from top tier financial content providers like Barchart.com, Tipranks.com, TradingView.com, Yahoo! Finance, and Zacks.com. The research and editorial team behind HTM consolidates this aggregated data into easily consumable reports used to produce articles, newsletters, and web content. The reports produced by HTM contain timely information stock analysis, stock price targets, earnings announcements, insider trades, dividends, and top moving stocks.
==============================================================================
